Inclusion Criteria:  Hospitalization for moderate to severe COVID-19, defined as ful-filling at a minimum the following clinical status category on the WHO 8-point ordinal scale: (i) "score 4" [oxygen via mask or nasal] Bio-ADM ≥50 pg/mL or ≥30% increase until the end of the next day (with a minimum of 35 pg/mL at all) DPP3 ≤50 ng/mL Age ≥18 years at time of screening Body weight ≤ 150 kg at time of screening  Exclusion Criteria:  Life expectancy less than 3 months before COVID-19 at the discretion of the Investigator Invasive mechanical ventilation ≥ 72 hours at time-point of randomization History of severe asthma, atopic allergy, severe immune or chronic inflammatory conditions (e.g. systemic lupus erythematosus) Resuscitation > 45 minutes Hypersensitivity to the active substance, to Adrecizumab or any of its excipients, or known serious hypersensitivity to other monoclonal antibodies Currently receiving systemic chemotherapy and/or radiotherapy Pre-existing severe chronic liver disease (i.e. Child-Pugh C) before COVID-19 hospitalization Pre-existing dialysis therapy before COVID-19 hospitalization